Join MIT VMS on Thursday, November 6 on Zoom for the next VMS Boot Camp: HR Foundations for Startup Founders. The session will be led by VMS mentor and Co-Director Carlton V. Aird and run from 10AM-2PM.
Sourcemap: Supply chain transparency platform Leonardo Bonanni, Founder and CEO, Sourcemap
Tamr: Cloud-native data mastering solution for unprecedented scaling and reduced costs Mitch Tompkins, Sales Manager, Tamr
Sensai Analytics: Scaling Enterprise AI Ian Mathews. CEO & Co-founder, Sensai Analytics
ThruWave: 3D millimeter wave image sensors for verification and efficiency in industrial and commercial applications Matt Reynolds, Founder & CEO, ThruWave
Jeeva: Re-imagining Connectivity to Automate Consumable Replenishment Scott Bright,CEO, Jeeva
Investing in Science Based Startups
MIT STARTUP EXCHANGE JUNE 2024 DEMO DAY
June 6, 2024
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Akkio makes it incredibly easy to build and deploy machine learning predictive models. Optimize your sales pipeline, reduce churn, forecast demand, and more -- easier and faster than ever before.